Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Host Response and Inflammation

Role of Activated Protein C in Helicobacter pylori-Associated Gastritis

Satoko Oka, Esteban Cesar Gabazza, Yukiko Taguchi, Michihiko Yamaguchi, Shigehito Nakashima, Koji Suzuki, Yukihiko Adachi, Ichiro Imoto
Satoko Oka
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esteban Cesar Gabazza
The Third Department of Internal Medicine and the
Department of Molecular Pathobiology, Mie University School of Medicine, Tsu, Mie, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukiko Taguchi
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michihiko Yamaguchi
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigehito Nakashima
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Suzuki
Department of Molecular Pathobiology, Mie University School of Medicine, Tsu, Mie, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukihiko Adachi
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ichiro Imoto
The Third Department of Internal Medicine and the
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.68.5.2863-2869.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The protein C (PC) pathway has recently been suggested to play a role in the regulation of the inflammatory response. To further extend the anti-inflammatory effect of activated PC (APC) in vivo, particularly its biological relevance to human disease, the activity of APC in the mucosa of patients with Helicobacter pylori-associated gastritis and the effect of vacuolating cytotoxin (VacA), cytotoxin-associated antigen (CagA), andH. pylori lipopolysaccharide (LPS) on PC activation were evaluated. This study comprised 35 patients with chronic gastritis. There were 20 patients with and 15 without H. pylori infection. The levels of PC and APC-PC inhibitor (PCI) complex were measured by immunoassays. The level of PC was significantly decreased and the level of APC-PCI complex was significantly increased in biopsy specimens from gastric corpus and antrum in patients with H. pylori-associated gastritis as compared to H. pylori-negative subjects. The concentrations of VacA, CagA, and LPS were significantly correlated with those of the APC-PCI complex in biopsy mucosal specimens from the gastric corpus and antrum. H. pylori LPS, VacA, and CagA induced a dose-dependent activation of PC on the surface of monocytic cells. APC inhibited the secretion of tumor necrosis factor alpha (TNF-α) induced by H. pylori LPS. Overall, these results suggest that H. pylori infection is associated with increased APC generation in the gastric mucosa. The inhibitory activity of APC on TNF-α secretion may serve to protect H. pylori-induced gastric mucosal damage.

Helicobacter pylori is the major causative factor of chronic atrophic gastritis and peptic ulcer disease (5, 18). Infection by this bacterium has more recently been identified as a risk factor for gastric cancer and as a causative factor of mucosa-associated lymphoid tissue lymphoma (15, 35). The virulence of H. pylori in the gastric mucosa has been associated with its ability to express cytotoxins (vacuolating cytotoxin [VacA], cytotoxin-associated antigen [CagA]) and various enzymes (urease, protease) and with its ability to induce the secretion of various cytokines from host cells (31). Most clinical isolates of H. pylori produce VacA, which causes vacuolar degeneration in several mammalian cell lines; VacA- and CagA-producing strains are associated with the more severe forms of disease, such as peptic ulcer and gastric cancer (31). Urease derived from H. pylori may induce tissue damage by catalyzing the formation of ammonia or indirectly by inducing oxidative bursts of neutrophils or by stimulating monocytes to secrete proinflammatory cytokines (7, 25, 31). The production of cytokines has an important role in H. pylori-associated gastroduodenal disease. Increased expression of tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-8, and IL-6 has been reported in culture supernatants of H. pylori-infected gastric biopsy specimens (10). The mRNA expressions of IL-7, IL-8, and IL-6 were also found to be significantly higher in H. pylori-infected subjects than in controls (49). Cytokines can function in the acute-phase response, in wound healing, and in defense mechanisms by amplifying the host immune response. However, increased and persistent production of cytokines may exaggerate the inflammatory response, thus exerting a deleterious effect on the host. Acute and chronic inflammation, intravascular thrombosis, tissue atrophy, and remodeling are among the pathologic conditions that have a significant cytokine component (10).

The protein C (PC) pathway constitutes the most important anticoagulant system that regulates the activation of blood coagulation (13, 42). The anticoagulant PC zymogen is converted to the serine protease activated PC (APC) by the thrombomodulin (TM)-thrombin complex on the phospholipid surface of endothelial cells, monocytes, and platelets. Classically, APC has been described to exert anticoagulant activity by catalyzing the proteolytic inactivation of the coagulation factors Va and VIIIa and profibrinolytic activity by inactivating plasminogen activator inhibitor type-1 (34). Recent studies suggested that, in addition to modulating the activation of blood coagulation, the PC pathway may also regulate the inflammatory response. Animal studies have demonstrated that systemic administration of APC prevents the lethal effects of Escherichia coli-induced sepsis and that it is effective for the treatment of patients with disseminated intravascular coagulation associated with meningococcemia and acquired PC deficiency (19, 38, 44). Data from these studies showed that APC may play a role in the inflammatory response by modulating the effects of cytokines, such as TNF-α, and by blocking neutrophil activation (32, 33). These observations have been supported by more recent in vitro studies in which it was shown that APC inhibits lipopolysaccharide (LPS), phorbol ester, and gamma-interferon-induced production of proinflammatory cytokines and that APC suppresses E-selectin-mediated inflammatory cell adhesion to endothelial cells (20, 23). Exacerbation of the response of primates to sublethal levels ofE. coli and the increased circulating levels of TNF-α after inhibition of protein S, a glycoprotein that enhances the effect of APC, also support the thesis that PC has a regulatory role in the inflammatory response (45).

To further extend the anti-inflammatory effect of APC in vivo, particularly its biological relevance to human disease, in the present study, we evaluated the activity of APC in the mucosa of patients withH. pylori-associated gastritis. The effect of cytotoxins and LPS derived from H. pylori on PC activation and the inhibitory activity of APC on H. pylori-derived LPS-induced secretion of TNF-α were also investigated.

MATERIALS AND METHODS

Reagents.Cary-Blair medium was purchased from Oxoid Unipath Ltd. (Hampshire, United Kingdom), and M-BHM pylori agar was purchased from Nikken Chemicals (Kyoto, Japan). Recombinant VacA toxin, recombinant CagA from H. pylori, and polyclonal anti-VacA and anti-CagA antibodies were purchased from Austral Biologicals (San Ramon, Calif.). Bovine serum albumin (BSA), RPMI 1640 medium, and recombinant hirudin and aprotinin (an inhibitor of APC) were from Sigma Chemical (St. Louis, Mo.), and the APC chromogenic substrate, S-2366, was from Chromogenix AB (Molndal, Sweden). Penicillin and streptomycin were from Nacalai Tesque (Kyoto, Japan), and fetal bovine serum (FBS) was from Gibco BRL (Grand Island, N.Y.). WST-1[2-(iodophenyl)-3- (4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium-Na] was purchased from Dojindo (Kumamoto, Japan). PC and thrombin were prepared from plasma as previously described (11, 43). All other chemicals and reagents used in this study were of the best quality commercially available.

Subjects and gastric endoscopy.This study comprised 35 patients (16 men and 19 women; age, 59.1 ± 12.2 [mean ± standard deviation] years with chronic gastritis. They consulted in our institution because of dyspepsia. The patients were categorized into H. pylori-positive (12 men and 8 women; age, 55.3 ± 10.5 years) and H. pylori-negative (4 men and 11 women; age, 47.2 ± 13.0 years) patients based on the results of serological tests for H. pylori, which was then confirmed by bacteriological studies as described below. Classification and grading of gastritis was done according to the Updated Sydney System (12). In the latter group of patients, dietary habits, alcohol intake, duodenal regurgitation, and stress were considered potential causative factors of gastritis. Further, for making comparison, patients with gastric (n = 13) and duodenal (n = 12) ulcer were also examined. None of the patients has undergone upper gastrointestinal surgery or had taken any drug over the previous 6 weeks. Gastric mucosal biopsy was performed by endoscopy in all subjects. Gastric endoscopy was carried out in the morning before breakfast, using an endoscope (Olympus Co., Tokyo, Japan). Patients fasted from 9:00 p.m. of the previous day until the time of endoscopy. Before endoscopy, the patients received pharyngeal anesthesia with lidocaine hydrochloride and an intramuscular injection of atropine sulfate (0.5 mg) and scopolamine butylbromide (20 mg). An intravenous injection of diazepam (5 mg) was additionally administered to some patients showing reactivity during the endoscopy study. The study protocol was approved by the Mie University Hospital Institutional Review Board, and it was carried out following the principles of the Helsinski Declaration.

Preparation of biopsy specimen homogenates.During the gastric endoscopy, four biopsy samples were obtained from the middle portion of the gastric body and the antrum along the greater curvature. Two specimens were used for H. pylori culture and histological examination, and the remaining specimens were used for preparing homogenates. After sampling, biopsy specimens for preparing homogenates were immediately washed several times in phosphate-buffered saline (PBS) and stored at −80°C until use. Homogenization of biopsy specimens were carried out in 1 ml of PBS containing leupeptin (1 μg/ml), p-amidinophenyl-methanesulfonyl fluoride-hydrochloride (0.1 μM), aprotinin (1 μg/ml), and pepstatin-A (1 μg/ml) and by using the polytron homogenizer (Kinematica, Switzerland). The preparation was then centrifuged at 10,000 × g for 5 min, and the supernatants were used in the in vitro assays.

Immunoassays and measurement of protein and LPS concentrations.The levels of PC and PC inhibitor (PCI) in the supernatants of biopsy specimen homogenates and plasma were determined by a solid-phase immunoassay using a human polyclonal anti-PC or anti-PCI antibodies and biotin-labeled monoclonal anti-PC or anti-PCI antibodies as previously described (17, 34). PC and PCI values were extrapolated from a standard curve drawn by using standard values. The intra-assay and inter-assay coefficients of variation for both PC and PCI were less than 10%. The levels of APC-PCI complex in the supernatants and plasma were measured by enzyme-linked immunoassays as previously described (17). The values of APC-PCI complex were extrapolated from a curve drawn by using standard concentrations of the complex. The inter-assay and the intra-assay coefficients of variations were 5 and 9%, respectively. The levels of VacA and CagA antigens in the biopsy supernatants were measured by immunoassays. Briefly, polyclonal anti-VacA or anti-CagA antibody (5 μg/ml) was immobilized on microtiter wells by overnight incubation. After appropriate washing with enzyme immunoassay (EIA) buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.1% Tween 20, and 5% BSA), blocking of nonspecific binding was done with 5% BSA dissolved in PBS (100 mM phosphate buffer, 150 mM NaCl, pH 7.5). After 3 h of incubation, the wells were washed with EIA buffer, and 100 μl of gastric biopsy homogenates was added to each well and incubated overnight at 4°C. The wells were then washed with EIA buffer, and 100 μl (0.5 μg/ml) of biotin-labeled anti-VacA or anti-CagA antibody was added to the wells and incubated for 3 h. After washing, streptavidin-horseradish peroxidase conjugate (Amersham Promega Biotech, Buckinghamshire, United Kingdom) was added to the wells and incubated for 30 min. After washing, peroxidase substrate was added to each well, and absorbance was measured at 450 nm. The values of VacA or CagA were extrapolated from a standard curve drawn by using known concentrations of each toxin. The intra-assay and inter-assay coefficients of variations were less than 15%. The concentrations of thrombin-antithrombin complex (TAT) in gastric mucosal specimens and plasma were measured by immunoassays as described previously. Protein concentration in the supernatants was measured by the Bradford's method using a protein assay kit (Bio-Rad Laboratories, Hercules, Calif.). LPS in gastric biopsy homogenates was measured by using the Toxicolor System LS-6 set (Seikagaku Co., Tokyo, Japan).

Immunohistochemical study.Immunostaining of TM and monocytic cells in gastric biopsy samples was performed as described previously (30, 37). Briefly, gastric biopsy specimens were snap frozen and stored at −70°C after fixing with paraformaldehyde solution. Histological sections with a width of 5 μm were incubated with 1 μg of mouse monoclonal anti-human (TM) or anti-human CD68 antibody from Dako (Kyoto, Japan) per ml as first antibody. The samples were then treated successively with biotin-labeled rabbit anti-mouse immunoglobulin G, peroxidase-labeled streptavidin, and peroxidase substrate by using the Catalyzed Signal Amplification System from Dako.

H. pylori LPS preparation.LPS was prepared fromH. pylori ATCC 43504 by the hot-phenol-water method of Westphal and Jann (36, 48). In brief, the bacteria were scraped from blood agar into saline, centrifuged at 10,000 × g for 15 min, and then resuspended in distilled water with an equal volume of 90% phenol at 60°C for 15 min. The mixture was then cooled to 10°C and centrifuged at 10,000 × g for 15 min. The aqueous layer was pooled and the same procedure was repeated twice. The pooled water-extracted layers were then dialyzed for 72 h against several changes of distilled water. The structure of the LPS from H. pylori ATCC 43504 has been described to be composed of a hydrophobic lipid A moiety, a core oligosaccharide region, and an O-polysaccharide chain; the last one is a partially fucosylated N-acetyllactosaminoglycan chain containing a terminal Lewisx antigen (1). As a control, LPS purified by the hot-phenol-water from E. coli O55:B5 (Difco Laboratories, Detroit, Mich.) was used in each experiment.

Identification of H. pylori.After sampling, biopsy specimens were immediately placed in Cary-Blair medium and stored at 4°C until use. Within 3 h of collection, specimens were placed onto M-BHM pylori agar and then incubated at 37°C for 5 days in a low aerobic atmosphere created by using 10% of CO2 incubator. The presence of H. pylori in milky white semitransparent colonies suspected of containing H. pylori was examined by using various biochemical tests (urease, oxidase, catalase, and nitrate reduction tests). H. pylori was identified by examining, under a light microscope, formalin-fixed biopsy specimens stained with May Giemsa. H. pylori cells appeared as spiral rods with a width of about 0.5 μm and a length of about 3 μm. Patients were classified as H. pylori-positive if their biopsy specimens were positive for the organism in culture or histological examination and as H. pylori-negative when the organism was not detected in culture, by histological examination, or by biochemical tests.

Culture of THP-1 cells.THP-1 cells (American Type Culture Collection, Rockville, Md.) were cultured in RPMI medium supplemented with 10% FBS, 100 μg of penicillin/ml, 100 μg of streptomycin/ml, and 2 nM l-glutamine under an atmosphere of 95% air and 5% CO2.

Preparation of peripheral blood mononuclear cells.Peripheral blood mononuclear cells were obtained from healthy donors by vein puncture and using EDTA as an anticoagulant. Mononuclear cells were isolated by the Lymphoprep Tube (Nycorned Pharma Diagnostica, Oslo, Norway). The mononuclear cell phase, comprising monocytes and lymphocytes, was harvested, washed twice with RPMI medium (supplemented with 2 nmol of l-glutamine/liter, 100 μg of streptomycin/liter, 100 μg of penicillin/ml, 10% FBS), and resuspended in RPMI.

Assay of PC activation on monocyte cell surface.The ability of the monocytic cell lines to generate APC in the presence of PC and thrombin were evaluated as previously described (21). Briefly, THP-1 or peripheral blood mononuclear cells (1 × 106 to 2 × 106/well) were washed three times in reaction buffer (50 mM Tris-HCl, pH 7.5, containing 2 mM CaCl2 and 0.1% BSA). Cells were then incubated in 96-well plates in the presence of PC (5 μg/ml), thrombin (0.12 U/well), and reaction buffer in a final volume of 80 μl at 37°C, under an atmosphere of 95% air and 5% CO2. Thereafter, the plates were centrifuged at 11,000 × g for 5 min and the generation of APC was measured in the supernatants. Generation of APC was detected by cleavage of APC substrate S2366 by using a microplate ELISA reader. To prevent nonspecific cleavage of S2366 by thrombin, hirudin (250 antithrombin units/well) was added to each supernatant for 5 min at room temperature before testing for APC activation. PC activation was markedly expressed on both THP-1 and peripheral blood mononuclear cells (data not shown); thus, subsequent experiments were done by using only THP-1 cells.

Effect of biopsy specimen homogenates on PC activation in monocytic THP-1 cells.To determine the effect of gastric mucosal homogenate on PC activation, THP-1 cells (1 × 106cells/well) were cultured in RPMI medium (300 μl) containing heat-inactivated 10% FBS for 24 h in duplicate wells of 48-well tissue culture trays in the presence of supernatants of gastric mucosal homogenate (30 μl). The cells were then washed three times with reaction buffer, and then APC generation was measured as described above. APC values were extrapolated from a standard curve using known concentrations of APC.

Effect of VacA, CagA, and LPS from H. pylori on PC activation in THP-1 cells.To determine the effect of H. pylori-derived cytotoxins or LPS on PC activation, THP-1 cells (1 × 106 cells/well) were cultured for 24 h in duplicate wells of 96-well tissue culture trays in the presence of various concentrations of VacA, CagA, or LPS from H. pylori. The cells were then washed three times with reaction buffer, and then PC activation was measured as described above. The effect of inactive toxins on PC activation on THP-1 cells was also assessed; for these experiments, 10 μg of the toxins per ml were heat inactivated by incubating in reaction buffer at 100°C for 15 min and then used in the assays. VacA was also inactivated by treating with formaldehyde for 48 h at 37°C as described previously (28).

Effect of APC on LPS-induced expression of TNF-α by THP-1 cells.Supernatants were collected from THP-1 cells that were cultured in 96-well flat-bottom tissue culture plates in medium for 24 h in the presence of LPS (10 μg/ml) and various concentrations of APC and stored at −80°C until use. To evaluate the LPS dose dependency of APC effect on TNF-α expression, THP-1 cells were cultured in medium for 24 h in the presence of APC (15 μg/ml) and various concentrations of LPS (15 to 0 μg/ml). After centrifuging, the supernatants were collected and stored at −80°C until use. The concentration of human TNF-α in supernatants was measured by using a commercial immunoassay kit purchased from Biosource International (Camarillo, Calif.). The minimum detectable level of TNF-α was <0.09 pg/ml. The intra-assay and the inter-assay coefficients of variation of TNF-α were <5 and <10%, respectively.

Statistical analysis.Data are expressed as the mean ± the standard error. The difference between the mean of two variables was calculated by Student's t test and that between three or more variables by analysis of variance. A P value of <0.05 was considered statistically significant.

RESULTS

Gastric mucosal and plasma concentrations of PC and APC-PCI complex.The concentration of PC was significantly decreased in biopsy specimens from gastric corpus (7.5 ± 3.7 [mean ± standard error] versus 22.9 ± 11.5 pg/μg of protein) and antrum (1.8 ± 0.3 versus 3.1 ± 0.4 pg/μg of protein) in patients with H. pylori-associated gastritis as compared to that of H. pylori-negative subjects (Fig.1). The concentration of APC-PCI complex, an indicator of ongoing PC activation, was significantly increased in biopsy specimens from gastric corpus (13.9 ± 2.3 versus 7.8 ± 0.9 pg/μg of protein) and antrum (10.2 ± 1.6 versus 6.7 ± 0.7 pg/μg of protein) in H. pylori-positive gastritis patients as compared to those withoutH. pylori infection (Fig. 1). The patients were also classified according to the degree of gastric mucosal infiltration of neutrophils in active, inactive, and healthy groups. The APC-PCI complex level in mucosal specimens from corpus was significantly higher in the active group (14.5 ± 2.7 pg/μg of protein) than in the inactive (11.1 ± 3.5 pg/μg of protein) and healthy (7.7 ± 0.9 pg/μg of protein) groups. The gastric mucosal concentrations of APC-PCI tended to be higher, but not at a significant level, in patients infected with H. pylori positive for CagA compared to those infected with bacteria negative for this antigen. In addition, there was not a significant difference in the degree of mucosal PC activation among patients with gastritis or gastric and duodenal ulcer (data not shown). The plasma concentrations of PC and APC-PCI were not significantly different between patients with and without H. pylori infection (data not shown).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Levels of PC and APC-PCI complex in mucosal specimens from antrum and corpus in gastritis patients with and without H. pylori infection. The concentration of PC was significantly decreased in mucosal specimens from antrum and corpus in patients withH. pylori-associated gastritis as compared to H. pylori-negative subjects. The concentration of APC-PCI complex was significantly increased in biopsy specimens from antrum and corpus inH. pylori-positive gastritis patients as compared to those without H. pylori infection. Bars indicate mean ± standard error. ∗, P value of <0.05 when data were compared to data of H. pylori-negative patients.

Gastric mucosal and plasma concentrations of TAT.The concentrations of TAT, a marker of coagulation activation, in gastric mucosal specimens and plasma were not significantly different betweenH. pylori-positive and H. pylori-negative patients (data not shown).

PC activation on THP-1 cells induced by homogenates of gastric biopsy specimens, LPS, and cytotoxins.PC activation on the surface of THP-1 cells was significantly increased after overnight incubation of these cells with homogenate supernatants prepared from gastric biopsy specimens of patients with H. pylori-positive gastritis as compared to that induced by homogenate supernatants from biopsy specimens of H. pylori-negative gastritis patients and by buffer control (Fig. 2). To assess the effect of endotoxin and cytotoxins from H. pylori on PC activation by mononuclear cells, THP-1 cells were cultured overnight in the presence of various concentrations of H. pylori LPS, VacA, or CagA. H. pylori LPS induced a dose-dependent activation of PC on the surface of THP-1 cells. The degree of this PC activation was similar to that induced by E. coli-derived LPS (Fig. 3). Both VacA and CagA also increased the activation of PC in a dose-dependent manner (Fig.4). VacA increased PC activation from concentrations of 1 μg/ml, whereas CagA increased PC activation above concentrations of 3 μg/ml. Neither heat-inactivated toxins nor formaldehyde-inactivated VacA affected the activation of PC on THP-1 cells. H. pylori LPS, VacA, and CagA also similarly increased the activation of PC on peripheral blood monocytes from healthy donors (data not shown).

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

PC activation induced by homogenates from gastric biopsy specimens. PC activation on the surface of THP-1 cells was significantly increased after overnight incubation of these cells with homogenate supernatants prepared from gastric biopsy specimens (corpus) of patients with H. pylori-positive gastritis as compared to that induced by homogenate supernatants from biopsy specimens (corpus) of H. pylori-negative gastritis patients and by buffer control. Bars indicate mean ± standard error. ∗, Pvalue of <0.05 when data were compared to data of H. pylori-negative patients and control buffer.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

PC activation induced by H. pylori LPS on THP-1 cells. H. pylori LPS significantly (P< 0.05) induced a dose-dependent activation of PC on the surface of THP-1 cells. The degree of PC activation was similar to that induced byE. coli-derived LPS. Data are expressed as the percentage of PC activation over control (medium without LPS). Each value represents the mean ± standard error of triplicate determinations performed in four separate experiments.

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

PC activation induced by VacA and CagA on THP-1 cells. Both VacA and CagA significantly (P < 0.05) increased the activation of PC on THP-1 cells in a dose-dependent manner. Data are expressed as the percent of PC activation over control (medium without toxin). Each value represents the mean ± standard error of triplicate determinations performed in four separate experiments.

Relationship between the levels of APC-PCI complex and those of VacA, CagA, and LPS in the gastric mucosa of H. pylori-positive patients.In the gastric corpus, the concentrations of VacA, CagA, and LPS were 0.070 ± 0.02 [mean ± standard deviation], 2.3 ± 2.1, and 21.4 ± 2.7 pg/μg of protein, respectively. In antrum, the concentrations of VacA, CagA, and LPS were 0.10 ± 0.04, 1.1 ± 0.4, and 2.2 ± 0.2 pg/μg of protein, respectively. The concentrations of VacA (r = +0.7, P < 0.03), CagA (r = +0.9, P < 0.03), and LPS (r = +0.6, P < 0.04) were significantly correlated with those of APC-PCI complex in biopsy mucosal specimens from the gastric corpus. The concentrations of VacA (r = +0.6, P < 0.01), CagA (r = +0.7, P < 0.002), and LPS (r = +0.5, P < 0.05) were also significantly correlated with those of APC-PCI complex in biopsy mucosal specimens taken from the antrum. The relation of these H. pylori components with the degree of gastric inflammation was also investigated; the gastric mucosal level of VacA (r = +0.7, P < 0.01), but not that of CagA or LPS, was significantly correlated with the number of inflammatory cells in the gastric mucosa (mononuclear cells plus neutrophils).

Immunohistochemical staining of TM in the gastric mucosa.The gastric biopsy specimens from H. pylori-positive patients showed significant expression of immunoreactive TM in the subepithelial region of the gastric mucosa. Capillaries and monocytic phagocytes showed immunoreactivity of TM (Fig. 5A); some inflammatory cells migrating towards the gastric lumen were also found to stain positively for TM. Increased immunoreactivity of the monocytic phagocyte marker CD68 was also mainly observed in the subepithelial region of the gastric mucosa of H. pylori-positive patients (Fig. 5B). Staining of TM (Fig. 5C) or CD68 (Fig. 5D) was relatively weak in mucosal specimens fromH. pylori-negative patients.

Fig. 5.
  • Open in new tab
  • Download powerpoint
Fig. 5.

Immunohistochemical staining of TM and monocytes/macrophages in the gastric mucosa (×400). (A) Significant expression of immunoreactive TM can be observed in the subepithelial region of the gastric mucosa of patients with H. pyloriinfection; TM staining was observed on monocytic phagocytes and capillaries. (B) Increased immunoreactivity of the monocytic phagocyte marker CD68 was also observed in the gastric mucosa of H. pylori-positive patients. Immunoreactivity for TM (C) and CD68 (D) was weak in the mucosa of patients without H. pyloriinfection.

Effect of APC on cytokine production induced by H. pylori LPS.To assess the effect of APC on H. pylori LPS-induced secretion of TNF-α by THP-1 cells, these mononuclear cells were cultured overnight in the presence of LPS and various concentrations of APC. TNF-α levels were measured in the cell culture supernatants. As shown in Fig. 6, APC inhibited the secretion of TNF-α induced by H. pyloriLPS in a dose-dependent fashion. The inhibitory activity was significant above APC concentrations of 2 μg/ml. Incubation of APC in the presence of aprotinin (15 μM) blocked the inhibitory activity of APC on TNF-α secretion. The effect of APC on TNF-α secretion by THP-1 cells was LPS dose dependent. The inhibitory activity of APC on TNF-α secretion was found to be significantly effective at LPS concentrations between 10 and 2 μg/ml. The viability of the cells as measured by WST-1 was not affected by APC at any concentration used in the assay.

Fig. 6.
  • Open in new tab
  • Download powerpoint
Fig. 6.

Effect of APC on H. pylori LPS-induced TNF-α secretion from THP-1 cells. APC significantly inhibited the secretion of TNF-α induced by H. pylori LPS in a dose-dependent fashion. Each value represents the mean ± standard error of triplicate determinations performed in four separate experiments. Aprotinin-treated APC did not affect TNF-α secretion by THP-1 cells. ∗, P value of <0.05 when data were compared to data of control medium (medium with H. pylori LPS alone).

DISCUSSION

Following tissue injury, there is an exquisite interplay between coagulation, anticoagulation proteins, cytokines, adhesion molecules, and inflammatory cells in an attempt to resolve injury. The balance between these multiple interrelated factors are thought to be fundamental for the resolution of tissue injury. The PC natural anticoagulant pathway has been proposed to serve as a link between inflammation and coagulation (14). APC, the enzyme effector of the natural anticoagulant pathway, has also been found to have anti-inflammatory activity and to protect against organ damage by inhibiting the secretion of cytokines at site of inflammation (14, 33). To further extend the biological function of APC, we evaluated the role of this protease in the inflammatory response associated with H. pylori infection. The work reported here supports the concept that APC can play an important role in inflammation, particularly in the regulation of cytokine production. Our present results demonstrate that (i) APC formation is increased in the gastric mucosa of patients infected with H. pylori, (ii) PC activation is induced by LPS, VacA, and CagA derived from the bacterium, and (iii) APC inhibits the secretion of TNF-α induced byH. pylori LPS on monocytic cells.

The rate-limiting event in the generation of APC is the cellular availability of the membrane-bound glycoprotein TM. In the present study, compared to uninfected individuals, a high concentration of APC-PCI complex (an indicator of APC formation) was found in the gastric biopsy specimens of gastritis patients with H. pylori infection, suggesting that the bacterium stimulated TM expression in the gastric mucosa. In agreement with this, the immunohistochemical study also showed increased expression of TM in the gastric mucosa of patients infected with the bacterium. The cellular source of TM in the gastric mucosa is unclear, but endothelial cells and peripheral blood monocytes or macrophages, in which constitutive expression of functionally active TM has been previously demonstrated, could provide TM-rich cellular membrane to promote intramucosal APC formation (29, 42). However, based on the fact that colonization of H. pylori is restricted to the mucous layer and to the epithelial cell surface without affecting the intravascular space, TM on the surface of extravascular monocytes/macrophages may probably be the most important activators of PC in the gastric mucosa. This hypothesis is supported by the results of our immunohistochemical study showing increased staining of monocytic phagocytes in the gastric mucosa of H. pylori-infected subjects. Cytokines (e.g., TNF-α) and LPS may also increase the expression of TM from monocytes at sites of gastric inflammation (22, 39). To further clarify the role of monocytic cells for APC generation in the gastric mucosa infected with the bacterium, we compared the degree of PC activation on THP-1 cells induced by homogenates prepared from biopsy specimens of infected mucosa with that induced by homogenates prepared with uninfected gastric mucosa. Gastric biopsy specimens infected with H. pylori induced significant activation of PC on TPH-1 cells compared to uninfected specimens and control buffer, suggesting that monocytic cells play an important role in APC generation in theH. pylori-infected gastric mucosa.

Like other gram-negative bacteria, H. pylori contains LPS in its outer membrane. The biological activity of H. pylori LPS was reported to be low compared to other LPS from typical human pathogens known to induce significant toxic effects. For example,H. pylori LPS was found to induce immunological activity on human peripheral blood mononuclear cells and secretion of cytokines, such as TNF-α, IL-1, and IL-6, to a lesser extent than E. coli LPS (26). In the present investigation, whetherH. pylori and E. coli LPS also differ in their activity on the PC pathway was evaluated. Interestingly, H. pylori LPS enhanced PC activation in a similar fashion and to a similar extent as did LPS derived from E. coli. This finding strengthens the importance of APC formation as a humoral response to H. pylori infection in the gastric mucosa. The stimulatory effect of LPS on APC generation was previously reported to depend on an increased expression of TM on the cell surface of monocytic cells (21). Other virulence factors associated with H. pylori infection are the cytotoxins VacA and CagA. Several lines of evidence implicate a role for these toxins in H. pylori-associated gastroduodenal disease (2, 31, 46, 47); CagA may indirectly injure the gastric mucosa by inducing the expression of cytokines (10). Both VacA and CagA were found to induce increased APC generation on THP-1 cells in a dose-dependent manner. Further, the concentrations of VacA, CagA, and LPS were significantly correlated with those of APC-PCI complex in biopsy mucosal specimens from the corpus and antrum of the stomach. Overall, these findings suggest that H. pylori is equipped with an antigenic machinery that favors the activation of PC in the extravascular milieu of the gastric mucosa.

Infection with H. pylori results in mucosal increases in many proinflammatory and immunoregulatory cytokines and also increases in members of the chemokine group of peptides (10, 40). Although gastric mucosal cytokines are important for regulating cellular infiltration and activation, they may also be important in disease pathogenesis by contributing to mucosal damage and epithelial dysfunction (10). For example, TNF-α may damage endothelial cells, increase cellular permeability, and induce persistent release of oxygen free radicals from infiltrating neutrophils causing organ injury (4). Persistent epithelial cell activation and intracellular signalling induced by cytokines have been associated with the occurrence of intestinal metaplasia (6); cytokines have been also involved in alterations of gastric physiological responses leading to abnormal expression of gastrin, somatostatin, and gastrin-releasing peptides (3, 27). Several lines of evidence suggest that APC may prevent organ damage by inhibiting the production of cytokines (41, 44). In accord with this, in the present study, APC was found to inhibit the secretion of TNF-α induced by H. pylori on THP-1 cells. This finding suggests that APC generation may protect the gastric mucosa from H. pylori infection. The fact that aprotinin-treated APC did not inhibit cytokine production by H. pylori-stimulated monocytes also suggests that the serine protease activity of APC may be important for inhibiting cytokine production. Further, the recent identification of the APC receptor suggests that APC may directly exert anti-inflammatory activity by binding to its receptor on the cell surface (16, 24).

In summary, this study showed that H. pylori infection is associated with increased APC generation in the gastric mucosa and that this protease generation may serve to protectH. pylori-induced gastric mucosal damage.

Notes

Editor: J. D. Clements

FOOTNOTES

    • Received 7 September 1999.
    • Returned for modification 3 December 1999.
    • Accepted 2 February 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Aspinal G. O.,
    2. Moran A. P.
    Helicobacter pylori lipopolysaccharide structure and mimicry of Lewis blood group antigens Pathogenesis and host response in Helicobacter pylori infections. Moran A. P., O'Morain C. A. 1997 34 42 Bad Normed Verlag, International Medical Publishers Bad Homburg-Englewood, N.J
  2. 2.↵
    1. Atherton J. C.,
    2. Peek R. M.,
    3. Tham K. T.,
    4. Cover T. L.,
    5. Blaser M. J.
    Clinical and pathological importance of heterogeneity in VacA, the vacuolating cytotoxin gene of Helicobacter pylori.Gastroenterology11219979299
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Beales I. L. P.,
    2. Calam J.,
    3. Post L.
    Effect of transforming growth factor alpha and IL-8 on somatostatin release from canine fundic D cells.Gastroenterology1121997136143
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Berkow R. L.,
    2. Wang D.,
    3. Larrick J. W.,
    4. Dodson R. W.,
    5. Howard T. H.
    Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor.J. Immunol.139198737833791
    OpenUrlAbstract
  5. 5.↵
    1. Blaser M. J.
    Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.Gastroenterology1021992720727
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Crabtree J. E.,
    2. Wyatt J. I.,
    3. Perry S.,
    4. Playford R.,
    5. Ghosh P.,
    6. Calam J.
    CagA seropositive Helicobacter pylori infected non-ulcer patients have increased frequency of intestinal metaplasia.Gastroenterology1101996A85
    OpenUrlCrossRefWeb of Science
  7. 7.↵
    1. Crabtree J. E.
    Immune and inflammatory responses to Helicobacter pylori infection.Scand. J. Gastroenterol.31 (Suppl. 215)1996310
    OpenUrl
  8. 8.
    1. Crabtree J. E.,
    2. Shallcross T. M.,
    3. Heatley R. V.,
    4. Wyatt J. I.
    Mucosal tumour necrosis factor α and interleukin-6 in patients with Helicobacter pylori associated gastritis.Gut32199114731477
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Crabtree J. E.,
    2. Peichl P.,
    3. Wyatt J. I.,
    4. Stachl U.,
    5. Lindley I. J. D.
    Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection.Scand. J. Immunol.3719936570
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Crabtree J. E.
    Cytokines in the pathogenesis of Helicobacter pylori infections Pathogenesis and host response in Helicobacter pylori infections. Moran A. P., O'Morain C. A. 1997 128 139 Normed Verlag, International Medical Publishers Bad Homburg-Englewood, N.J
  11. 11.↵
    1. Deguchi H.,
    2. Takeya H.,
    3. Gabazza E. C.,
    4. Nishioka J.,
    5. Suzuki K.
    Prothrombin kringle 1 domain interacts with factor Va during the assembly of prothrombinase complex.Biochem. J.3211997729735
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Dixon M. F.,
    2. Genta R. M.,
    3. Yardley J. H.,
    4. Correa P.
    Classification and grading of gastritis.Am. J. Surg. Pathol.20199611611181
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Esmon C. T.
    The regulation of natural anticoagulant pathways.Science235198713481352
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Esmon C. T.,
    2. Taylor F. B. Jr.,
    3. Snow T. R.
    Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C.Thromb. Haemostasis661991160165
    OpenUrlPubMedWeb of Science
  15. 15.↵
    1. Forman D.,
    2. Newell D. G.,
    3. Fullerton F.,
    4. Yarnell J. W.,
    5. Stacey A. R.,
    6. Wald N.,
    7. Sitas F.
    Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.Br. Med. J.302199113021305
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Fukudome K.,
    2. Esmon C. T.
    Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor.J. Biol. Chem.26919942648626491
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Gabazza E. C.,
    2. Takeya H.,
    3. Deguchi H.,
    4. Sumida Y.,
    5. Taguchi O.,
    6. Murata K.,
    7. Nakatani K.,
    8. Yano Y.,
    9. Mohri M.,
    10. Sata M.,
    11. Shima T.,
    12. Nishioka J.,
    13. Suzuki K.
    Protein C activation in NIDDM patients.Diabetologia39199614551461
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Genta R. M.
    Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy.Gastroenterology1131997S51S55
    OpenUrlPubMedWeb of Science
  19. 19.↵
    1. Gerson W. T.,
    2. Dickerman J. D.,
    3. Bovill E. G.,
    4. Golden E.
    Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate.Pediatrics911993418422
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Grey S. T.,
    2. Tsuchida A.,
    3. Hau H.,
    4. Orthner C. L.,
    5. Salem H. H.,
    6. Hancock W. W.
    Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.J. Immunol.153199436643672
    OpenUrlAbstract
  21. 21.↵
    1. Grey S. T.,
    2. Hancock W. W.
    A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes.J. Immunol.156199622562263
    OpenUrlAbstract
  22. 22.↵
    1. Grey S. T.,
    2. Csizmadia V.,
    3. Hancock W. W.
    Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cells versus endothelial cells.Int. J. Hematol.6719985362
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Grinnell B. W.,
    2. Hermann R. B.,
    3. Yan S. B.
    Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide.Glycobiology41994221225
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Hancock W. W.,
    2. Grey S. T.,
    3. Hau L.,
    4. Akalin E.,
    5. Orthner C.,
    6. Sayegh M. H.,
    7. Salem H. H.
    Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signalling and monocyte-dependent proliferative responses.Transplantation60199515251528
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Harris P. R.,
    2. Mobley H. L. T.,
    3. Perez-Perez G. I.,
    4. Blaser M. J.,
    5. Smith P. D.
    Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production.Gastroenterology1111996419425
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Lee A.,
    2. Moran A. P.
    Lipopolysaccharide (LPS)-related damage by H. pylori Helicobacter pylori: basic mechanisms to clinical cure. Hunt R. H., Tytgat G. N. J. 1994 169 179 Kluwer Academic Publishers Dordrecht, The Netherlands
  27. 27.↵
    1. Levi S.,
    2. Beardshall K.,
    3. Haddad G.,
    4. Playfold R.,
    5. Ghosh P.,
    6. Calam J.
    Campylobacter pylori and duodenal ulcers: the gastrin link.Lancet1198911671168
    OpenUrlPubMedWeb of Science
  28. 28.↵
    1. Manetti R.,
    2. Massari P.,
    3. Marchetti M.,
    4. Magagnoli C.,
    5. Nuti S.,
    6. Lupetti P.,
    7. Ghiara P.,
    8. Rappuoli R.,
    9. Telford J. L.
    Detoxification of the Helicobacter pylori cytotoxin.Infect. Immun.65199746154619
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. McCachren S. S.,
    2. Diggs J.,
    3. Weinberg J. B.,
    4. Dittman W. A.
    Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages.Blood78199131283132
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Mizutani H.,
    2. Hayashi T.,
    3. Nouchi N.,
    4. Ohyanagi S.,
    5. Hashimoto K.
    Functional and immunoreactive thrombomodulin expressed by keratinocytes.J. Investig. Dermatol.1031994825828
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Mobley H. L.
    Helicobacter pylori factors associated with disease development.Gastroenterology1131997S21S28
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Murakami K.,
    2. Okajima K.,
    3. Uchiba M.,
    4. Johno M.,
    5. Nakagaki T.,
    6. Okabe H.,
    7. Takatsuki K.
    Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.Am. J. Physiol.2721997L197L202
    OpenUrlPubMedWeb of Science
  33. 33.↵
    1. Murakami K.,
    2. Okajima K.,
    3. Uchiba M.,
    4. Johno M.,
    5. Nakagaki T.,
    6. Okabe H.,
    7. Takatsuki K.
    Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.Blood871996642647
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Nishioka J.,
    2. Ning M.,
    3. Hayashi T.,
    4. Suzuki K.
    Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles.J. Biol. Chem.27319981128111287
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Parsonnet J.,
    2. Hansen S.,
    3. Rodriguez L.,
    4. Gelb A. B.,
    5. Warnke R. A.,
    6. Jellum E.,
    7. Orentreich N.,
    8. Vogelman J. H.,
    9. Friedman G. D.
    Helicobacter pylori infection and gastric lymphoma.N. Engl. J. Med.330199412671271
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Perez-Perez G. I.,
    2. Shepherd V. L.,
    3. Morrow J. D.,
    4. Blaser M. J.
    Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide.Infect. Immun.63199511831187
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Pratico D.,
    2. Iuliano L.,
    3. Mauriello A.,
    4. Spagnoli L.,
    5. Lawson J. A.,
    6. Rokach L.,
    7. Maclouf J.,
    8. Violi F.,
    9. FitzGerald G. A.
    Localization of distinct F2-isoprostanes in human atherosclerotic lesions.J. Clin. Investig.100199720282034
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Rivard G. E.,
    2. David M.,
    3. Farrel C.,
    4. Schwarz H. P.
    Treatment of purpura fulminans in meningococcemia with protein C concentrate.J. Pediatr.1261995646652
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Satta N.,
    2. Freyssinet J. M.,
    3. Toti F.
    The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide.Br. J. Haematol.961997534542
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Shimoyama T.,
    2. Crabtree J. E.
    Mucosal chemokines in Helicobacter pylori infection.J. Physiol. Pharmacol.481997315323
    OpenUrlPubMedWeb of Science
  41. 41.↵
    1. Snow T. R.,
    2. Deal M. T.,
    3. Dickey D. T.,
    4. Esmon C. T.
    Protein C activation following coronary artery occlusion in the in situ porcine heart.Circulation841991293299
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Suzuki K.
    Protein C Molecular basis of thrombosis and hemostasis. High K. A., Roberts H. R. 1996 393 412 Dekker New York, N.Y
  43. 43.↵
    1. Suzuki K.,
    2. Stenflo J.,
    3. Dahlback B.,
    4. Teodorson B.
    Inactivation of human coagulation factor V by activated protein C.J. Biol. Chem.258198319141920
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Taylor F. B. Jr.,
    2. Chang A.,
    3. Esmon C. T.,
    4. D'Angelo A.,
    5. Vigano-D'Angelo S.,
    6. Blick K. E.
    Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.J. Clin. Investig.791987918925
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Taylor F.,
    2. Chang A.,
    3. Ferrel G.,
    4. Mather T.,
    5. Catlett R.,
    6. Blick K.,
    7. Esmon C. T.
    C4b-binding protein exacerbates the host response to Escherichia coli.Blood781991357363
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. van Doorn L. J.,
    2. Figueiredo C.,
    3. Sanna R.,
    4. Plaisier A.,
    5. Schneeberger P.,
    6. de Boer W.,
    7. Quint W.
    Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori.Gastroenterology11519985866
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. van der Hulst R. W.,
    2. van der Ende A.,
    3. Dekker F. W.,
    4. Ten Kate F. J.,
    5. Weel J. F.,
    6. Keller J. J.,
    7. Kruizinga S. P.,
    8. Dankert J.,
    9. Tytgat G. N.
    Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study.Gastroenterology11319972530
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Wesphal O.,
    2. Jann K.
    Bacterial lipopolysaccharides.Methods Carbohydr. Chem.519658391
    OpenUrl
  49. 49.↵
    1. Yamaoka Y.,
    2. Kita M.,
    3. Kodama T.,
    4. Sawai N.,
    5. Imanishi J.
    Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa.Gastroenterology110199617441752
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Role of Activated Protein C in Helicobacter pylori-Associated Gastritis
Satoko Oka, Esteban Cesar Gabazza, Yukiko Taguchi, Michihiko Yamaguchi, Shigehito Nakashima, Koji Suzuki, Yukihiko Adachi, Ichiro Imoto
Infection and Immunity May 2000, 68 (5) 2863-2869; DOI: 10.1128/IAI.68.5.2863-2869.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Role of Activated Protein C in Helicobacter pylori-Associated Gastritis
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Role of Activated Protein C in Helicobacter pylori-Associated Gastritis
Satoko Oka, Esteban Cesar Gabazza, Yukiko Taguchi, Michihiko Yamaguchi, Shigehito Nakashima, Koji Suzuki, Yukihiko Adachi, Ichiro Imoto
Infection and Immunity May 2000, 68 (5) 2863-2869; DOI: 10.1128/IAI.68.5.2863-2869.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Notes
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antigens, Bacterial
gastritis
Helicobacter Infections
Helicobacter pylori
Protein C

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522